FDA GLP-1 Ban: What Patients Need to Know
- the FDA's action restricts access to compounded GLP-1 medications, perhaps affecting individuals relying on these alternatives for weight management adn diabetes treatment due to cost or availability issues.
- Food and drug Administration (FDA) ban on compounded GLP-1 drugs, including versions of popular weight-loss medications, took effect May 22.
- The ban follows shortages of brand-name semaglutide and tirzepatide injections, such as Ozempic and Wegovy (Novo Nordisk) and Zepbound and Mounjaro (Eli Lilly), starting in 2022.
The FDA has banned compounded GLP-1 drugs, impacting those using these medications for weight loss. This action,effective may 22,stems from shortages of brand-name drugs like Ozempic and Wegovy. The FDA cites safety risks, urging patients to consult doctors about switching to brand-name options. While custom formulations may still be available, be aware that compounded medications are not FDA-reviewed. Learn more about this crucial shift, discover how News Directory 3 is covering the story, and discover what’s next for patients.
FDA Ban on Compounded GLP-1s Impacts Weight Loss Medications
Updated May 25, 2025
A U.S. Food and drug Administration (FDA) ban on compounded GLP-1 drugs, including versions of popular weight-loss medications, took effect May 22. Individuals who have been using these compounded medications will likely need to find choice sources for their prescriptions.
The ban follows shortages of brand-name semaglutide and tirzepatide injections, such as Ozempic and Wegovy (Novo Nordisk) and Zepbound and Mounjaro (Eli Lilly), starting in 2022. High demand, coupled with limited insurance coverage and high prices, fueled the market for compounded GLP-1s, according to Mike DiStefano, PhD, assistant professor at the Center for Pharmaceutical Outcomes Research at the University of Colorado in Anschutz.
Compounding pharmacies were previously permitted to create copies of drugs facing shortages. However, with GLP-1 supply issues resolved, the FDA has moved to restrict the practice, citing safety concerns. the FDA warns that compounded drugs are not FDA-reviewed and may pose risks such as overdosing, unapproved ingredients, and counterfeit versions.
“I think that there is general agreement that these medications cost too much and not enough people have access to them, but I think very few people think that compounding them solves the problem due to the safety risks,” Nate Wood, MD, New Haven Primary Care Consortium said.
What’s next
Despite the ban, pharmacies may still be able to compound patient-specific formulations to meet unique needs, such as allergies to inactive ingredients. Experts anticipate some companies may attempt to offer “custom” compounded options, requiring prescriptions from willing providers.